Commitments and Contingencies - Additional Information (Details) € in Thousands		1 Months Ended									3 Months Ended
	May 16, 2022 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2022 USD ($)	Jan. 31, 2022 USD ($)	Jul. 31, 2019 USD ($)	Dec. 31, 2014 USD ($) LicensedProduct	Jan. 31, 2014 USD ($)	Sep. 30, 2013 USD ($)	Jul. 31, 2011 USD ($)	Nov. 30, 2009 EUR (€)	Mar. 31, 2025 USD ($) OperatingLease	Mar. 31, 2024 USD ($)
Lessee Lease Description [Line Items]
Estimated payments due											$ 26,836,000
Operating lease liabilities											18,444,000
Research and development expenses											23,343,000	$ 17,052,000
National Institute of Health
Lessee Lease Description [Line Items]
License issue royalty fee								$ 100,000
Sales milestone payments								600,000
Development and regulatory milestone payments								$ 700,000
Patent licensing reimbursement fees											30,000.00
Royalty Bearing Patent License Agreement
Lessee Lease Description [Line Items]
License agreement term										10 years
Royalty Bearing Patent License Agreement \| IND Filings
Lessee Lease Description [Line Items]
Potential milestone payments \| €										€ 10
Clearside
Lessee Lease Description [Line Items]
Expenses											0	0
Upfront payment					$ 100,000
Royalties on net sales					20.00%
License agreement expiration period					10 years
Clearside \| Maximum
Lessee Lease Description [Line Items]
Aggregate milestones payment					$ 21,000,000
LI-COR, Inc. \| 2014 Exclusive Agreement
Lessee Lease Description [Line Items]
One-time upfront license issuance fee							$ 100,000
Research and development expenses											0	0
License agreement expiration period							10 years
LI-COR, Inc. \| 2014 Exclusive Agreement \| Maximum
Lessee Lease Description [Line Items]
Aggregate milestone payments							$ 200,000
LI-COR, Inc. \| 2014 Non- Exclusive Agreement
Lessee Lease Description [Line Items]
License issue fee						$ 30,000.00
Milestone payments											0	0
LI-COR, Inc. \| 2014 Non- Exclusive Agreement \| Maximum
Lessee Lease Description [Line Items]
Payments for development and commercial milestones						$ 400,000
Life Technologies
Lessee Lease Description [Line Items]
Number of licensed products \| LicensedProduct						5
Initial license fee						$ 100,000
Initial license fee for first licensed product			$ 400,000
Initial license fee for additional licensed product			500,000
Payment for sublicense			200,000
Payment for use of cell line document package			30,000.00
Annual development fee						100,000
Non-refundable, Non- creditable fee						300,000
Change of control fees			$ 500,000			200,000
One time perpetual license agreement fee				$ 50,000.00
Expenses											0	0
Expense related to agreement including sublicense											0	0
Dr. John Schiller \| 2014 Non- Exclusive Agreement
Lessee Lease Description [Line Items]
Required amendment payment		$ 60,000.00
Required amendment payment due period		30 days
Dr. John Schiller \| Collaboration Research and Development Agreement
Lessee Lease Description [Line Items]
Annual development fee									$ 30,000.00
Agreement term									2 years
First payment due									30 days
Subsequent payments due									30 days
Research collaboration fees											$ 0	$ 0
Dr. John Schiller \| Collaboration Research and Development Agreement \| 10th Anniversary
Lessee Lease Description [Line Items]
Required amendment payment		$ 50,000.00
Required amendment payment due period		30 days
Rakuten \| 2014 Non- Exclusive Agreement
Lessee Lease Description [Line Items]
License issue fee						30,000.00
Rakuten \| 2014 Non- Exclusive Agreement \| Maximum
Lessee Lease Description [Line Items]
License issue fee						$ 300,000
Office and Laboratory Facility
Lessee Lease Description [Line Items]
Number of operating lease \| OperatingLease											1
Estimated payments due	$ 35,200,000
Lease commencement date	Aug. 01, 2022
Operating lease, option to extend term	7 years
Letters of credit	$ 800,000
Maximum reimbursement cost	$ 500,000
Incurred of expenses related to expansion											$ 500,000

Aura Biosciences, Inc. 10-Q